Meningococcal serogroup C vaccination in students of a faculty of medicine: Coverage and perceptions

被引:0
作者
Vaysse, B. [1 ]
Joly, A. [2 ]
Ganry, O. [1 ]
Gignon, M. [1 ,3 ]
机构
[1] CHU Amiens Picardie, Dept Desante Publ, F-80054 Amiens, France
[2] Univ Picardie Jules Verne, Dept Med Gen, F-80000 Amiens, France
[3] Univ Sorbonne Paris Cite, Lab Educ & Prat Sante, EA 3412, F-93017 Bobigny, France
关键词
Vaccination; Medical students; Meningococcal meningitis; NEISSERIA-MENINGITIDIS; RISK-FACTORS; DISEASE; CARRIAGE; ASSOCIATION; POPULATION;
D O I
10.1016/j.admp.2014.10.008
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. Our region is facing a situation of hyperendemic meningococcal disease (MD) with the implementation of a targeted vaccination campaign against serogroup B in 2009. Students are a population at risk. Knowing the perception of medical students on vaccination will improve education and information. Objectives. The objectives of the study were to assess immunization coverage of medical students against meningococcal serogroup C with a focus on those from hyperendemic districts, to explore their representation of the meningitis vaccine, and seek promoting factors and barriers to vaccination. Methods. A descriptive survey was conducted from self-administered questionnaires available to all students of a French medical school. A logistic regression analysis was performed to identify factors influencing vaccination. Results. The response rate was 51.6%, or 562 usable questionnaires. The declarative rate of this vaccination is 21.8%. Factors positively influencing the immunization status are the recent discussion of vaccination status, being up to date with mandatory vaccinations and young age. Reasons for non-vaccination are the lack of proposal (29.3%), lack of information (19.3%) and lack of opportunity (12.4%). The students are mostly in favor of vaccinations (87.3%). Being native of hyperendemic MD B districts does not influence their position or their vaccination status. Among the students, 52.2% consider themselves to he at risk of MD because of their medical studies. Conclusion. Information about vaccines should be systematic for students admitted to the second year, before their clinical training. Preventive health services, occupational health care services, academic and student associations can contribute to it. (C) 2014 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:237 / 244
页数:8
相关论文
共 50 条
  • [21] Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial
    van Ravenhorst, Mariette B.
    van der Klis, Fiona R. M.
    van Rooijen, Debbie M.
    Knol, Mirjam J.
    Stoof, Susanne P.
    Sanders, Elisabeth A. M.
    Berbers, Guy A. M.
    VACCINE, 2017, 35 (36) : 4745 - 4752
  • [22] Evidence for Rise in Meningococcal Serogroup C Bactericidal Antibody Titers in the Absence of Booster Vaccination in Previously Vaccinated Children
    Badahdah, Al-Mamoon
    Khatami, Ameneh
    Tashani, Mohamed
    Rashid, Harunor
    Booy, Robert
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2018, 37 (03) : E66 - E71
  • [23] The Impact of the Meningococcal Serogroup C Conjugate Vaccine in Canada Between 2002 and 2012
    Sadarangani, Manish
    Scheifele, David W.
    Halperin, Scott A.
    Vaudry, Wendy
    Le Saux, Nicole
    Tsang, Raymond
    Bettinger, Julie A.
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (09) : 1208 - 1215
  • [24] Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt
    Greenwood, Brian
    VACCINE, 2013, 31 (11) : 1453 - 1457
  • [25] Serogroup C meningococci in Italy in the era of conjugate menC vaccination
    Stefanelli, Paola
    Fazio, Cecilia
    Sofia, Tonino
    Neri, Arianna
    Mastrantonio, Paola
    BMC INFECTIOUS DISEASES, 2009, 9 : 135
  • [26] Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)
    Bettinger, Julie A.
    Scheifele, David W.
    Halperin, Scott A.
    Vaudry, Wendy
    Findlow, Jamie
    Borrow, Ray
    Medini, Duccio
    Tsang, Raymond
    VACCINE, 2013, 32 (01) : 124 - 130
  • [27] Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy
    Neri, Arianna
    Fabiani, Massimo
    Barbui, Anna Maria
    Vocale, Caterina
    Miglietta, Alessandro
    Fazio, Cecilia
    Carannante, Anna
    Palmieri, Annapina
    Vacca, Paola
    Stefanelli, Paola
    Ambrosio, Luigina
    VACCINES, 2022, 10 (05)
  • [28] Kinetics of Immune Responses to Nasal Challenge With Meningococcal Polysaccharide One Year After Serogroup-C Glycoconjugate Vaccination
    Wing, James B.
    Smart, Lynne
    Borrow, Ray
    Findlow, Jamie
    Findlow, Helen
    Heath, Andrew W.
    Read, Robert C.
    CLINICAL INFECTIOUS DISEASES, 2011, 52 (11) : 1317 - 1323
  • [29] Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine
    Borrow, R
    Richmond, P
    Kaczmarski, EB
    Iverson, A
    Martin, SL
    Findlow, J
    Acuna, M
    Longworth, E
    O'Connor, R
    Paul, J
    Miller, E
    FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2000, 28 (01): : 79 - 85
  • [30] Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine
    Sakou, Irine-Ikbale
    Tzanakaki, Georgina
    Tsolia, Maria N.
    Sioumala, Maria
    Barbouni, Anastasia
    Kyprianou, Miltiades
    Papaevangelou, Vana
    Tsitsika, Artemis
    Blackwell, Caroline C.
    Kafetzis, Dimitris
    Kremastinou, Jenny
    VACCINE, 2009, 27 (33) : 4408 - 4411